{rfName}
Tr

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Romeo MCorresponding AuthorPardo JcAuthorMartinez-Balibrea EAuthorQuiroga VAuthorMargelí MAuthorMesía RAuthor
Share
Publications
>
Review

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer.

Publicated to:International Journal Of Molecular Sciences. 19 (10): 3249- - 2018-10-19 19(10), DOI: 10.3390/ijms19103249

Authors: Romeo, M; Pardo, JC; Martínez-Cardús, A; Martínez-Balibrea, E; Quiroga, V; Martínez-Román, S; Solé, F; Margelí, M; Mesía, R

Affiliations

Campus de la UAB, Universitat Autónoma de Barcelona, Plaça Cívica, 08193 Bellaterra, Spain. mromeo@iconcologia.net. - Author
Germans Trias & Pujol Fdn IGTP, Hlth Sci Res Inst, B ARGO Grp, Carretera Canyet S-N, Badalona 08916, Spain - Author
Gynecology Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain. smartinezro.germanstrias@gencat.cat. - Author
Health Sciences Research Institute of the Germans Trias i Pujol Foundation (IGTP), B-ARGO Group, Carretera del Canyet s/n, 08916 Badalona, Spain. amartinezc@igtp.cat. - Author
Hlth Sci Res Inst Germans Trias & Pujo IGTP, Program Predict & Personalized Canc Med PMPPC, Inst Catala Oncol Badalona, Program Canc Therapeut Resistance ProCURE, Carretera Can Ruti,Cami Escoles S-N, Badalona 08916, Spain - Author
Hosp Badalona Germans Trias & Pujol, Gynecol Dept, Badalona 08916, Spain - Author
Inst Catala Oncol Badalona, B ARGO Grp, Med Oncol Dept, Carretera Canyet S-N, Badalona 08916, Spain - Author
Inst Recerca Leucemia Josep Carreras, Badalona 08916, Spain - Author
Institut de Recerca contra la Leucemia Josep Carreras, 08916 Badalona, Spain. fsole@carrerasresearch.org. - Author
Medical Oncology Department, B-ARGO Group, Institut Català d'Oncologia Badalona, Carretera del Canyet s/n, 08916 Badalona, Spain. jcpardor@iconcologia.net. - Author
Medical Oncology Department, B-ARGO Group, Institut Català d'Oncologia Badalona, Carretera del Canyet s/n, 08916 Badalona, Spain. mmargeli@iconcologia.net. - Author
Medical Oncology Department, B-ARGO Group, Institut Català d'Oncologia Badalona, Carretera del Canyet s/n, 08916 Badalona, Spain. mromeo@iconcologia.net. - Author
Medical Oncology Department, B-ARGO Group, Institut Català d'Oncologia Badalona, Carretera del Canyet s/n, 08916 Badalona, Spain. rmesia@iconcologia.net. - Author
Medical Oncology Department, B-ARGO Group, Institut Català d'Oncologia Badalona, Carretera del Canyet s/n, 08916 Badalona, Spain. vquiroga@iconcologia.net. - Author
Program against Cancer Therapeutic Resistance (ProCURE), Institut Català d'Oncologia Badalona, Program for Predictive and Personalized Cancer Medicine (PMPPC), Health Sciences Research Institute Germans Trias i Pujo (IGTP), Carretera de Can Ruti, Camí de les Escoles s/n, 08916 Badalona, Spain. embalibrea@iconcologia.net. - Author
Univ Autonoma Barcelona, Campus UAB,Placa Civ, Bellaterra 08193, Spain - Author
See more

Abstract

Keywords
Brca1Brca2Breast-cancerDeficient homologous recombinationDna-repairDouble-blindFallopian-tubeHigh-grade serous ovarian cancerMechanisms of resistanceOlaparib maintenance therapyOvarian cancerParp inhibitor rucaparibParp inhibitorsPlatinum-sensitive ovarianPoly(adp-ribose) polymeraseRandomized phase-2 trialSerous ovarian

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal International Journal Of Molecular Sciences due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2018, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Computer Science Applications. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-05-22:

  • WoS: 6
  • Scopus: 6
  • Europe PMC: 3
  • OpenCitations: 5
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-22:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 31.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 31 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 0.25.
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Romeo Marin, Margarita) and Last Author (Mesia Nin, Ricard).

the author responsible for correspondence tasks has been Romeo Marin, Margarita.